Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.60 |
| ▸ | PPARD | Q03181 | 8/20 | 0.60 |
| ▸ | PPARG | P37231 | 5/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13817870 | 1.00 | PPARA (0.60) | PPARAPPARDPPARGABCG2BCHE | |
| SCHEMBL13764711 | 0.91 | PPARA (0.63) | PPARAPPARDPPARGABCG2BCHE | |
| SCHEMBL814668 | 0.91 | PPARA (0.63) | PPARAPPARDPPARGABCG2BCHE | |
| SCHEMBL1934560 | 0.91 | PPARA (0.48) | PPARAPPARDPPARGABCG2BCHE | |
| SCHEMBL11893163 | 0.91 | PPARA (0.48) | PPARAPPARDPPARGABCG2BCHE | |
| SCHEMBL11893218 | 0.88 | PPARA (0.67) | PPARAPPARDPPARGABCG2BCHE | |
| SCHEMBL13764726 | 0.85 | PPARA (0.70) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL11893152 | 0.85 | ABCG2 (0.58) | ABCG2BCHEACHE | |
| SCHEMBL4464438 | 0.85 | ABCG2 (0.58) | ABCG2BCHEACHE | |
| SCHEMBL13764718 | 0.84 | PPARA (0.69) | PPARAPPARDPPARGABCG2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701938-B1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2012-07-25 | — | — | EP | claimed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | claimed |
| JP-2007517841-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | claimed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | claimed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2018-10-04 | — | — | US | disclosed |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-07-17 | — | — | US | disclosed |
| EP-2641596-B1 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-05-02 | — | — | EP | disclosed |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-12-28 | — | — | US | disclosed |
| US-9782373-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2012-10-04 | — | — | US | disclosed |
| EP-2504005-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | Genfit (FR) | 2012-10-03 | — | — | EP | disclosed |
| EP-1701938-B1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011064350-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2011-06-03 | — | — | WO | disclosed |
| US-7547729-B2 | 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same | GENFIT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | disclosed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | TYR, DHPS, DDT | PPARA 14/4885PPARD 23/4885PPARG 64/4885 |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARA 65/4885PPARD 94/4885PPARG 119/4885 |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARA 65/4885PPARD 94/4885PPARG 119/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARA 65/4885PPARD 94/4885PPARG 119/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | PPARA 65/4885PPARD 94/4885PPARG 119/4885 |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT1, GOT2 | PPARA 251/4885PPARD 349/4885PPARG 315/4885 |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | PPARA 65/4885PPARD 94/4885PPARG 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.